Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
McKinsey
Baxter
McKesson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,211,229

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,211,229 protect, and when does it expire?

Patent 6,211,229 protects SILENOR and is included in one NDA.

Summary for Patent: 6,211,229
Title: Treatment of transient and short term insomnia
Abstract:The invention is directed to a method for the treatment of a patient suffering from transient or short term insomnia. The claimed method comprises the administration of a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof in dosages ranging from about 0.5 to about 20.0 milligrams.
Inventor(s): Kavey; Neil B. (Chappaqua, NY)
Assignee:
Application Number:09/506,348
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,211,229
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,211,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 RX Yes No   Start Trial   Start Trial TREATMENT OF INSOMNIA   Start Trial
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 RX Yes Yes   Start Trial   Start Trial TREATMENT OF INSOMNIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
AstraZeneca
Baxter
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.